Hospital Universitari de Tarragona Joan XXIII -ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2020

  1. UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

    Leukemia, Vol. 34, Núm. 11, pp. 2925-2933

2015

  1. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia

    Blood Cancer Journal, Vol. 5, pp. e352

  2. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature

    Oncotarget, Vol. 6, Núm. 31, pp. 31613-31627

2014

  1. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia

    Leukemia

2013

  1. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

    Leukemia, Vol. 27, Núm. 11, pp. 2157-2164

2011

  1. Mortality risk factors in patients with zygomycosis: A retrospective and multicentre study of 25

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 4, pp. 263-268

2009

  1. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy

    Leukemia, Vol. 23, Núm. 3, pp. 486-491